TransMedics Group Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? TransMedics Group Inc trades at $87.58 (market cap $3.10B), while Direxion Daily FTSE China Bull 3x Shares trades at $28.92. Which is the better fit depends on your goals.
| TMDX | YINN | |
|---|---|---|
Market Cap | $3.10B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $150.42 | $56.62 |
52-Week Low | $61.99 | $21.45 |
Enterprise Value | $3.49B | — |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
YINN, a leveraged ETF tracking the FTSE China Bull 3x strategy, trades at $28.93, down 10.43% in 24 hours amid broad bearish technical signals. The fund lacks traditional financial ratios due to its structure, with a dividend of $0.21 scheduled for June 2026. Recent news highlights China's economic stimulus and AI investments, but geopolitical tensions and regulatory risks persist.
Outlook remains cautious due to leverage amplifying volatility; opportunities exist if Chinese equities rebound, but risks include US-China friction and economic slowdowns. Investors should weigh the ETF's high-risk profile against potential gains from China's tech growth initiatives.
Trailing returns across standard periods
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →